Your shopping cart is currently empty

XYD190 (Compound 14g) is an orally active degrader of CBP/p300. It inhibits the bromodomain of CBP/p300 with an IC50 of 483.7 nM and demonstrates antitumor activity against acute myeloid leukemia.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | Inquiry | Inquiry | |
| 50 mg | Inquiry | Inquiry | Inquiry |
| Description | XYD190 (Compound 14g) is an orally active degrader of CBP/p300. It inhibits the bromodomain of CBP/p300 with an IC50 of 483.7 nM and demonstrates antitumor activity against acute myeloid leukemia. |
| In vitro | XYD190, at concentrations ranging from 0 to 1 μM over 72 to 120 hours, inhibits the proliferation of acute myeloid leukemia (AML) cells MV4;11, MOLM-13, and MOLM-16, with IC50 values of 1.8, 26.9, and 4.6 nM, respectively. Additionally, at concentrations of 0 to 150 nM for 6 hours, XYD190 induces the degradation of CBP and p300 in the bromodomain protein family in a CRBN and protease-dependent manner. |
| In vivo | CBP/p300 ligand 4, administered orally at 5 mg/kg every other day for two weeks, demonstrates antitumor activity in the MV4;11 xenograft mouse model, achieving a tumor growth inhibition (TGI) rate of 88%. |
| Formula | C55H50F2N10O7 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.